ARTICLE
19 December 2024

Intas Expands Cancer Therapy Biosimilar Portfolio

GP
Goodwin Procter LLP

Contributor

At Goodwin, we partner with our clients to practice law with integrity, ingenuity, agility, and ambition. Our 1,600 lawyers across the United States, Europe, and Asia excel at complex transactions, high-stakes litigation and world-class advisory services in the technology, life sciences, real estate, private equity, and financial industries. Our unique combination of deep experience serving both the innovators and investors in a rapidly changing, technology-driven economy sets us apart.
On December 3, 2024, Accord BioPharma, Inc. ("Accord"), the U.S. specialty division of Intas Pharmaceuticals, Ltd. ("Intas"), announced an agreement to acquire...
United States Food, Drugs, Healthcare, Life Sciences

On December 3, 2024, Accord BioPharma, Inc. ("Accord"), the U.S. specialty division of Intas Pharmaceuticals, Ltd. ("Intas"), announced an agreement to acquire Coherus BioSciences, Inc.'s UDENYCA® (pegfilgrastim-cbqv) business. UDENYCA®, the only biosimilar to Amgen's NEULASTA® in the United States, is administered the day after chemotherapy treatment to decrease the incidence of infection by febrile neutropenia. The acquisition "will expand Accord BioPharma's product portfolio and is expected to position the company for accelerated growth in the biosimilar industry."

The UNDENYCA® acquisition follows an announcement last month that Intas and Xbrane Biopharma AB ("Xbrane") entered into an exclusive global licensing and co-development agreement for Xbrane's nivolumab biosimilar candidate. Nivolumab, currently commercialized by Bristol Myers Squibb as OPDIVO®, is a monoclonal antibody used in cancer immunotherapy. Under the terms of the agreement, Intas will finance and oversee clinical and regulatory development and global commercialization, and Xbrane will receive an upfront payment of 10 million EUR, development milestone payments of 3 million EUR, and, after launch, double-digit royalties on profits. According to Martin Åmark, CEO of Xbrane, the parties are "very well positioned to bring [their] Nivolumab biosimilar candidate to launch at the time of patent expiration of Opdivo® in the US in December 2028 and June 2030 in Europe and generate significant profit sharing from that point and onwards. . . . By making these foundational therapies more accessible, biosimilars enable healthcare systems to allocate more resources towards innovative combination treatments, which have the potential to improve over treatment outcomes."

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

Mondaq uses cookies on this website. By using our website you agree to our use of cookies as set out in our Privacy Policy.

Learn More